US10582286B2 - Method for treating debilitating hyperacusis - Google Patents
Method for treating debilitating hyperacusis Download PDFInfo
- Publication number
- US10582286B2 US10582286B2 US16/450,023 US201916450023A US10582286B2 US 10582286 B2 US10582286 B2 US 10582286B2 US 201916450023 A US201916450023 A US 201916450023A US 10582286 B2 US10582286 B2 US 10582286B2
- Authority
- US
- United States
- Prior art keywords
- patient
- ear
- loudness
- sound
- sound generator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010020559 Hyperacusis Diseases 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims abstract description 52
- 238000011282 treatment Methods 0.000 claims abstract description 69
- 238000009223 counseling Methods 0.000 claims abstract description 44
- 230000001629 suppression Effects 0.000 claims abstract description 40
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 5
- 208000026935 allergic disease Diseases 0.000 claims abstract description 5
- 230000009610 hypersensitivity Effects 0.000 claims abstract description 5
- 230000013707 sensory perception of sound Effects 0.000 claims description 88
- 238000012360 testing method Methods 0.000 claims description 40
- 238000007906 compression Methods 0.000 claims description 39
- 230000006835 compression Effects 0.000 claims description 38
- 230000004044 response Effects 0.000 claims description 33
- 238000012795 verification Methods 0.000 claims description 24
- 230000001965 increasing effect Effects 0.000 claims description 22
- 210000005069 ears Anatomy 0.000 claims description 21
- 238000012545 processing Methods 0.000 claims description 19
- 238000005259 measurement Methods 0.000 claims description 15
- 230000007704 transition Effects 0.000 claims description 13
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- 230000002618 waking effect Effects 0.000 claims description 7
- 230000003467 diminishing effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 description 28
- 210000004556 brain Anatomy 0.000 description 27
- 206010011878 Deafness Diseases 0.000 description 21
- 231100000888 hearing loss Toxicity 0.000 description 21
- 230000010370 hearing loss Effects 0.000 description 21
- 208000016354 hearing loss disease Diseases 0.000 description 21
- 230000006870 function Effects 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 210000003477 cochlea Anatomy 0.000 description 14
- 208000009205 Tinnitus Diseases 0.000 description 13
- 230000003321 amplification Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 206010052804 Drug tolerance Diseases 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 210000002768 hair cell Anatomy 0.000 description 11
- 230000002739 subcortical effect Effects 0.000 description 11
- 231100000886 tinnitus Toxicity 0.000 description 11
- 230000026781 habituation Effects 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 9
- 230000008447 perception Effects 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 9
- 206010011891 Deafness neurosensory Diseases 0.000 description 8
- 210000003984 auditory pathway Anatomy 0.000 description 8
- 230000002996 emotional effect Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 210000000613 ear canal Anatomy 0.000 description 7
- 210000000067 inner hair cell Anatomy 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 230000006461 physiological response Effects 0.000 description 7
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 7
- 210000003926 auditory cortex Anatomy 0.000 description 6
- 238000003339 best practice Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000272173 Calidris Species 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000003454 tympanic membrane Anatomy 0.000 description 5
- 238000013022 venting Methods 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000000883 ear external Anatomy 0.000 description 4
- 210000003027 ear inner Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000004081 cilia Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000959 ear middle Anatomy 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 206010049119 Emotional distress Diseases 0.000 description 2
- 101000579226 Homo sapiens Renin receptor Proteins 0.000 description 2
- 206010054956 Phonophobia Diseases 0.000 description 2
- 102100028254 Renin receptor Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 210000002939 cerumen Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000005015 neuronal process Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000002578 otoscopy Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical group C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000000477 Bilateral Hearing Loss Diseases 0.000 description 1
- 208000023914 Central Auditory disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010011903 Deafness traumatic Diseases 0.000 description 1
- 208000036828 Device occlusion Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000032041 Hearing impaired Diseases 0.000 description 1
- 206010063491 Herpes zoster oticus Diseases 0.000 description 1
- 208000000258 High-Frequency Hearing Loss Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010048533 Hypervigilance Diseases 0.000 description 1
- 206010049977 Intracranial hypotension Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000027115 auditory system disease Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 210000000721 basilar membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011554 ferrofluid Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 201000011349 geniculate herpes zoster Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000885 high-frequency hearing loss Toxicity 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000012625 in-situ measurement Methods 0.000 description 1
- 210000003552 inferior colliculi Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 206010033103 otosclerosis Diseases 0.000 description 1
- 231100000199 ototoxic Toxicity 0.000 description 1
- 230000002970 ototoxic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000011295 pitch Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002480 semicircular canal Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04R—LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS
- H04R25/00—Deaf-aid sets, i.e. electro-acoustic or electro-mechanical hearing aids; Electric tinnitus maskers providing an auditory perception
- H04R25/35—Deaf-aid sets, i.e. electro-acoustic or electro-mechanical hearing aids; Electric tinnitus maskers providing an auditory perception using translation techniques
- H04R25/356—Amplitude, e.g. amplitude shift or compression
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04R—LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS
- H04R1/00—Details of transducers, loudspeakers or microphones
- H04R1/10—Earpieces; Attachments therefor ; Earphones; Monophonic headphones
- H04R1/1016—Earpieces of the intra-aural type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
- A61F11/06—Protective devices for the ears
- A61F11/08—Protective devices for the ears internal, e.g. earplugs
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04R—LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS
- H04R25/00—Deaf-aid sets, i.e. electro-acoustic or electro-mechanical hearing aids; Electric tinnitus maskers providing an auditory perception
- H04R25/50—Customised settings for obtaining desired overall acoustical characteristics
- H04R25/505—Customised settings for obtaining desired overall acoustical characteristics using digital signal processing
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04R—LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS
- H04R25/00—Deaf-aid sets, i.e. electro-acoustic or electro-mechanical hearing aids; Electric tinnitus maskers providing an auditory perception
- H04R25/75—Electric tinnitus maskers providing an auditory perception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0027—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the hearing sense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3375—Acoustical, e.g. ultrasonic, measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/08—Supports for equipment
- A61M2209/088—Supports for equipment on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0662—Ears
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04R—LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS
- H04R2420/00—Details of connection covered by H04R, not provided for in its groups
- H04R2420/07—Applications of wireless loudspeakers or wireless microphones
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04R—LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS
- H04R2460/00—Details of hearing devices, i.e. of ear- or headphones covered by H04R1/10 or H04R5/033 but not provided for in any of their subgroups, or of hearing aids covered by H04R25/00 but not provided for in any of its subgroups
- H04R2460/01—Hearing devices using active noise cancellation
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04R—LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS
- H04R25/00—Deaf-aid sets, i.e. electro-acoustic or electro-mechanical hearing aids; Electric tinnitus maskers providing an auditory perception
- H04R25/50—Customised settings for obtaining desired overall acoustical characteristics
- H04R25/502—Customised settings for obtaining desired overall acoustical characteristics using analog signal processing
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04R—LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS
- H04R25/00—Deaf-aid sets, i.e. electro-acoustic or electro-mechanical hearing aids; Electric tinnitus maskers providing an auditory perception
- H04R25/55—Deaf-aid sets, i.e. electro-acoustic or electro-mechanical hearing aids; Electric tinnitus maskers providing an auditory perception using an external connection, either wireless or wired
- H04R25/558—Remote control, e.g. of amplification, frequency
Definitions
- This invention relates to treatment of hyperacusis. Specifically, the invention provides a method of treatment of hyperacusis using a novel behind-the-ear device and counseling protocol.
- Hyperacusis is an unusual intolerance to the loudness of an ordinary environment. Patients suffering from hyperacusis have an abnormally strong reaction to sounds within the auditory system that is manifested by inordinate discomfort to sound that would not evoke a similar reaction in the average listener. The estimated prevalence of hyperacusis in the general population is between about 0.6% and 15%. About 85%-90% of hyperacusis patients have an associated tinnitus condition. (Anari et al. 1999; Nelting 2002). It has been reported that up to about 55% of patients with tinnitus also have hyperacusis. (Schecklmann et al. 2014).
- phonophobia is a specific type of phobia in which the individual has a persistent, abnormal and unwarranted fear of sound.
- the resulting hypervigilance accounts for the exaggerated behavior in a patient's awareness to the sound environment.
- Patients having hyperacusis may also exhibit symptoms of misophonia in which the individual experiences a strong, unpleasant reaction to ordinary sounds. This selective sensitivity to specific sounds may be accompanied by emotional distress and behavioral responses such as avoidance. In some instances, patients may also have pain associated with the hyperacusis. Neither hyperacusis, misophonia nor phonophobia have any relation to hearing thresholds. In hyperacusis, the auditory system is not working poorly but rather, it is working too well and overcompensating to a change in the normal gain setting of the auditory system.
- Hyperacusis is associated with several peripheral and central auditory diseases as well as many non-auditory diseases.
- Exemplary disorders exhibiting hyperacusis symptoms include otosclerosis; efferent dysfunction; TMJ dysfunction; Bell's palsy; Meniere's disease; perilymphatic fistula; acute acoustic trauma; Lyme disease; autism; traumatic head injury; migraines; depression; childhood learning disability; diminished serotonin function; central auditory pathway lesions; William's syndrome; intracranial hypotension; myasthenia gravis; and Ramsey Hunt syndrome.
- the auditory system is comprised of the outer ear, the middle ear and the inner ear as shown in FIG. 1 .
- the outer ear is comprised of the pinna, the structure visible from the outside. It captures and directs sound waves into the ear canal, which in turn cause mechanical vibration of the eardrum.
- Behind the eardrum is the middle ear, which is an air-filled space that has a chain of 3 interconnected small bones. A sound wave vibrates the eardrum which vibrates the three bones. The third bone moves like a piston in and out of a membranous window at the entrance to the inner ear.
- the outer and middle ear facilitate sound transmission to the inner ear.
- the inner ear has 2 primary components: the balance system and the cochlea.
- the balance system has 3 semicircular canals that have nerve endings which send spatial information to the brain to balance and associate the body's position in space.
- the cochlea is the sensory organ for hearing.
- the cochlea is a hollow tube filled with fluid that spirals around and a membrane that has hair cells positioned on and spiraling around the tube.
- a hair cell has 3 parts: a main body (largest part), cilia at the top that are the tiny little hair fibers atop the main body and a connection to the nerve.
- Cilia can be thought of as mini hair cells that move back and forth when there's fluid motion inside the cochlea. When we hear a sound, there is movement of the fluid, bending of the membrane supporting the main hair cells, and bending of the cilia back and forth. This movement activates the big hair cells to send the auditory electrical signal via the nerve fibers to the brain.
- the hair cells transform mechanical energy (fluid motion) into an electrochemical signal so that the brain can process it.
- IHCs inner hair cells
- OHCs outer hair cells
- IHCs are the primary sensory transducers of sound with 95% of the connecting neural fibers carrying auditory signals from the cochlea to the brain, where the signal is recognized as sound. Neural activity from IHCs go in one direction and receive little or no input back from the brain.
- the IHCs are sheltered and protected from damage more than the OHCs, which have a different function.
- the OHCs boost the strength of the auditory signal and fine tune it.
- the OHCs have the ability to amplify sounds instantaneously, up to 60 dB, to help the IHCs boost sounds if someone is talking softly or to attenuate sounds if they are loud.
- OHCs send signals or impulses along the nerve fibers going up to the brain, but, unlike the IHCs, they have large numbers of nerve fibers coming from the brain back to the OHCs thus OHCs have control from the brain.
- This unique innervation characteristic suggests that the OHCs contribute to the instantaneous gain adjustment to sound, but the primary gain mechanism giving rise to hyperacusis is likely at the higher central level of the auditory system, above the cochlea.
- OHCS are very vulnerable to damage from noise, ototoxic drugs, viral infections and aging. Fortunately, OHCs are abundant; it has been estimated that humans could lose up to 30% of OHCs, spread evenly throughout the cochlea and still have normal puretone hearing thresholds.
- the basilar membrane is frequency specific, meaning that different frequencies stimulate the cochlea at different locations.
- the high frequency (HF) hair cells are located at the entrance of the cochlea where neural fibers are stimulated, and low frequency (LF) structures are stimulated and located distally to the entrance.
- the hair cells that respond to the higher frequencies, at the entrance to the cochlea, are more vulnerable to wear and tear which is why high frequency hearing loss is experienced more than low frequency hearing loss.
- FIG. 2 highlights the complex auditory neural pathways arising from the cochlea, carrying auditory signals to the auditory cortex. This is the ascending pathway. There is an equally complex descending pathway from the auditory cortex back to the cochlea that is not shown here. The complex interactions between these two pathways control the gain of the auditory system.
- the primary central gain mechanism presumably reflects processing in the subcortical areas.
- An example of the representation of “gain” is a dial that is normally set to 0. When the dial is turned clockwise there is an increase in central auditory gain, giving rise to the perception of a louder signal which is manifested by decreased LDLs consistent with hyperacusis. However, when the dial is turning back toward 0, the LDLs increase as the auditory gain is reduced and the signal is perceived to be less loud, which in turn results in expansion of the dynamic range. There is a constant low level of activity happening within the auditory pathways at all times. When everything is silent within the listening environment, there is an ongoing low level of neuronal activity. In hyperacusis, there is a form of neural hyperactivity ongoing.
- Gain is being adjusted (increased or decreased) in the subcortical areas. More specifically, some research suggests that the inferior colliculus has an important role in gain adjustment because this is where auditory information is first integrated by the two ears.
- Primary hyperacusis is almost always, if not solely, a bilateral problem and therefore an auditory pathway problem. The problem arises from abnormally elevated gain within the auditory pathways, which is represented by the reduced LDLs and reduced tolerance to sounds. Thus, whatever the cause or trigger of hyperacusis has resulted in increased auditory gain. If a patient wears earplugs to prohibit sound from coming into the system, the brain realizes that there is reduced or zero input and in response increases the gain of the system.
- a hyper-gain system sound is transmitted to the peripheral ear (cochlea and nerve) as in the normal-gain system.
- FIG. 4 In the normal-gain system, neuronal processes in the auditory subcortical areas are operating in a state of equilibrium in terms of their excitatory and inhibitory actions. Abnormal changes in either set of actions can give rise to increased central auditory gain and hyperacusis. Moreover, if the subcortical areas view the signal as different, dangerous or new, then the subcortical processing enhances the associated neuronal activity, i.e. the dial registers this increase as a change in the gain setting. If the mechanisms that control auditory system gain abnormally amplify a signal, then the result is the perception of an abnormally loud sound in the auditory cortex thus resulting in primary hyperacusis.
- the protocol was adopted into tinnitus retraining therapy (TRT). (Hazell & Sheldrake 1992).
- Formby et al. examined the effect of counseling on patients having bilateral hearing loss with and without use of noise generators in a randomized, placebo-controlled study. It was found that treatment that included both counseling as well as noise generators was more efficacious than either treatment alone. (Formby et al. 2015)
- Sammeth et al. developed a sound-limiting infinite compression device that was used for management of debilitating hyperacusis.
- the loudness suppression devices were housed in in-ear casings and supplied low-level amplification followed by an extreme form of amplitude compression for moderate or high level inputs to reduce loudness discomfort without reducing audibility. (Sammeth et al. 2000).
- FIG. 5 illustrates the relative level change when using earplugs versus using a noise generator.
- Current best practices treatment focuses on noise generators and counseling; however, patients may have difficulty with the transition from earplugs/earmuffs to a noise generator device and fear any device or method related to amplification.
- the current treatment for hyperacusis includes the use of noise generators and counseling to expand the dynamic range, however an intermediate step with sound protection is needed. This step is counterproductive because wearing sound protection can exacerbate hyperacusis and prevents effective delivery of sound therapy.
- the invention described below overcomes a major dilemma—the patient's desire to wear sound protection rather than wearing and using a sound-therapy device. Given the shortcomings of current therapies for hyperacusis, what is needed is a therapy that is able to recalibrate the abnormal gain associated with hyperacusis by using the natural plasticity of the auditory system that is specifically tailored to the needs of the specific patient.
- the inventors have developed a method for treating hyperacusis involving a novel transitional device incorporating EPs and sound generators (SGs) and a formal treatment protocol to transition the patient from EPs towards normal audition.
- SGs EPs and sound generators
- a formal treatment protocol to transition the patient from EPs towards normal audition.
- This mold includes a heat-activated stint that expands at body temperature to augment the normal seal, functioning as a high-quality, custom EP.
- a miniature behind-the-ear hearing device is connected to the earmold via slim probe tube. The device has four key functions in addition to the attenuation provided by the EP.
- An on-board SG creates a low-level, spectrally-shaped noise and is configurable for individual patients.
- the SG also serves to reduce auditory gain and increase sound tolerance.
- amplification approaches unity gain over time to overcome the maladaptive plasticity associated with earplugs.
- output limiting reduces the exposure to loud, offending sounds. If the patient has aidable hearing loss, then the device can function as a fully-featured hearing aid.
- a fitting protocol has been developed so that the patient can realize the desired benefit of this novel treatment device.
- real-ear measures quantify unaided gain, occluded gain, the noise response, and the aided unity gain needed to overcome earplugging.
- Output limiting (loudness compression), imposed under conditions of unity gain, minimizes exposure to loud sounds while providing access to soft and comfortably loud sounds typically attenuated by an EP that otherwise exacerbates hyperacusis.
- a real-ear noise response is measured and adjusted to the desired spectral shape. The patient undergoes counseling on use, care, goals, and expectations that the low-level noise will enhance sound tolerance. On subsequent visits, the resulting SG-induced increases in loudness tolerance determine the release of loudness suppression and the transition of the patient from EPs to normal device-free audition, ultimately offering an effective treatment for debilitating hyperacusis.
- a method of diminishing hypersensitivity to sound in a patient in need thereof comprising: providing an in-ear hearing device; counseling the patient on loudness suppression and the sound generator; adjusting loudness compression thresholds based on a patient's frequency-specific loudness discomfort levels; fitting the sound generator to the patient by configuring the sound generator to a set level corresponding to a patient-specific soft loudness judgement; and systematically increasing the loudness compression thresholds to transition the patient to normal hearing.
- the in-ear hearing device is comprised of two interchangeable earmolds wherein one earmold is closed and another earmold is open wherein the earmolds conform substantially to the diameter and geometry of the patient's ear; a behind the ear shell connected to one of the earmolds by tubing; a receiver, sound generator component, at least one microphone and a signal processing component containing an amplifier all contained within the shell; and fitting software capable of controlling adjustment of noise generation and loudness suppression compression in the hearing device;
- the patient may wear either device for as long as can be tolerated by the patient in the waking day, preferably for at least 8 hours per waking day.
- the open earmold may swapped for the closed mold and may be worn by the patient when in a controlled sound environment where no unexpected sounds are present.
- the closed mold is worn by the patient when the patient expects to be exposed to an uncontrolled sound environment.
- a method of treating hyperacusis in a patient in need thereof comprising: providing an in ear hearing device; connecting the device to a programming computer; measuring the real ear unaided response (REUR); counseling the patient on the hearing devices; fitting the hearing devices with the closed molds to each ear of the patient; counseling the patient on the sound generator; fitting the sound generator to the patient by configuring the sound generator to a set level corresponding to a patient-specific soft loudness judgement; and systematically increasing the loudness compression thresholds to transition the patient to normal hearing.
- REUR real ear unaided response
- the in-ear hearing device may be comprised of two interchangeable earmolds wherein one earmold is a closed mold and the other earmold is an open mold which conform substantially to the diameter and geometry of the patient's ear; tubing connecting one of the two interchangeable earmolds to a behind the ear shell; at least one microphone, a receiver, a sound generator and a signal processor core containing an amplifier electrically connected and contained within the behind the ear shell; fitting software capable of controlling adjustment of noise generation and loudness suppression compression in the hearing device.
- Fitting the hearing devices with the closed molds to each ear of the patient may comprise the steps of: positioning each hearing device so that the earmold of the hearing device is inserted into one of the patient's ears wherein one ear is a test ear and the other ear is a non-test ear; estimating a verification noise floor; measuring real ear occluded response (REOR) by muting the sound generator, amplifier and microphones and administering a broadband or white noise from verification system speakers in the test ear; measuring real ear aided response (REAR); adjusting a gain-frequency response so that the REAR matches the REUR curve to achieve unity gain and result in real-ear insertion gain (REIG) that is 0 dB across frequency; adjusting loudness compression thresholds based on a patient's frequency-specific loudness discomfort levels; and repeating the above steps for the other device in the non-test ear.
- REOR real ear occluded response
- REIG real-ear insertion gain
- Fitting the sound generator to the patient may comprise the steps of inserting the one hearing device into each of the test and non-test ears of the patient; activating the sound generator of the hearing device in the test ear of the patient to emit a low-level broadband noise; establishing a level with the patient where the noise is perceived to be comfortable but soft according to the Contour Loudness Test Category 3; varying loudness of the noise and obtaining categorical loudness judgments on the noise from the patient; measuring real-ear sound generator (RESG) level to quantify SG output; repeating above steps for the hearing device in the non-test ear; and balancing both devices.
- RSG real-ear sound generator
- the method may also include administering audiometric testing to the patient prior to providing the hearing device to the patient.
- the method may include muting the receiver and amplifier and the at least one microphone of both hearing devices with the sound generator off prior to inserting the hearing devices into the patient's ears.
- the sound generator may be calibrated after estimating the noise floor by unmuting the sound generator and administering a white noise stimulus in the test ear.
- the data from REOR, REUR and noise floor may be compared to reference data in the fitting software.
- the REAR may be measured by the steps comprising: muting the sound generator; unmuting the receiver and amplifier and microphones; administering a broadband or white noise stimulus to the test ear; having the patient categorize loudness of the stimulus; and increasing a frequency of the stimulus at intervals until the patient reports loudness category 6 categorical judgment.
- the patient may wear both devices for at least 8 hours per waking day.
- the open earmold may swapped for the closed mold and may be worn by the patient when in a controlled sound environment where no unexpected sounds are present.
- the closed mold is worn by the patient when the patient expects to be exposed to an uncontrolled sound environment.
- Both devices are balanced by activating the both devices simultaneously and adjusting each device to have equal loudness.
- a system for use in treatment of hyperacusis in a patent in need thereof comprising: a hearing device; fitting software capable of controlling adjustment of noise generation and loudness suppression in the hearing device; verification software capable of connecting with the fitting software wherein the verification software provides reference data for comparison with patient data; and a counseling protocol wherein the counseling protocol provides counseling for both the sound generator and the loudness suppression.
- the hearing devices may be comprised of: two interchangeable earmolds wherein one earmold is a closed mold and the other earmold is an open mold which conform substantially to the diameter and geometry of the patient's ear; tubing connecting one of the two interchangeable earmolds to a behind the ear shell; and at least one microphone, a receiver, a sound generator and a signal processor core containing an amplifier electrically connected and contained within the behind the ear shell.
- the hearing devices are inserted into the patient's ears and loudness compression thresholds are adjusted based on a patient's frequency-specific loudness discomfort levels.
- the sound generator is fitted to the patient by configuring the sound generator to a set level corresponding to a patient-specific soft loudness judgement.
- the loudness compression thresholds are systematically increased to transition the patient to normal hearing.
- FIG. 1 is an image depicting the anatomy of the human ear.
- FIG. 2 is an image depicting the afferent auditory pathways.
- FIG. 3 is a flow chart of the normal-gain system.
- FIG. 4 is a flow chart of the loudness hyperacusis modeled hyper-gain system.
- FIG. 5 a graph depicting changes in gain with earplugs versus noise generators. (Formby et al. 2003).
- FIG. 6 is a flow chart of the hyper-gain system with emotional associations and physiological responses.
- FIG. 7 is a flow chart of the hyper-gain system with emotional associations and habituation of physiological responses.
- FIG. 8 is a flow chart of the hyper-gain system and habituation of emotional associations and physiological responses.
- FIG. 9 is a flow chart of the normal-gain system following recalibration of gain and habituation of emotional associations and physiological responses.
- FIG. 10 is a table illustrating how loudness is perceived for individuals with normal sensitivity versus individuals with hyperacusis. The table also illustrates how loudness is perceived when earplugs are worn versus when sound generators are worn.
- FIG. 11 is a graph depicting recruitment versus hyperacusis.
- Recruitment refers to “normal loudness” for high sound levels while hyperacusis refers to “uncomfortably loud” for moderate sound levels with an abnormally reduced dynamic range (DR).
- DR abnormally reduced dynamic range
- the image depicts an example of a person with hyperacusis and hearing loss. As noted in the image, the reports do not join the normal curve, but instead reach uncomfortable levels at a much lower level thus the reduced dynamic range is both due to the hearing loss and the lower LDL.
- FIG. 12 is a series of graphs depicting audiograms taken of a patient suffering from tinnitus and hyperacusis. As shown in the graphs, the patient's LDLs were low at the beginning of treatment and then improved over the course of treatment. (Formby and Gold 2002).
- FIG. 13 is a series of exemplary audiograms depicting audiometric thresholds and LDLs, bilaterally, for individuals with normal hearing sensitivity and typical sound tolerance, sensorineural hearing loss with loudness recruitment, and hyperacusis with normal hearing sensitivity.
- Pure tone thresholds are shown for the left ear by the cross or X symbols and for the right ear by the circles.
- Uncomfortable listening levels (UCL) are indicated by the U symbols.
- the figure on the left represents normal hearing with a normal dynamic range.
- the figure in the middle represents mild sloping to moderately severe sensorineural hearing loss with a reduced dynamic range due to hearing loss.
- the figure on the right represents normal thresholds and reduced dynamic range due to hyperacusis (Sandlin and Olsson, 1999).
- FIG. 14 is a table illustrating dynamic range versus loudness hyperacusis. Sensitivity to sound/hyperacusis is defined as a dynamic range less than 60 dB. (Goldstein et al. 1996).
- FIG. 15 is a perspective image of the device showing a closed mold earmold.
- FIG. 16 is a perspective image of the device showing an open mold earmold.
- FIG. 17 is a cross-sectional image taken along line 17 of FIG. 16 depicting the components located within the behind the ear shell of the novel device.
- FIG. 18 is an image of an on-semi chipset of the signal processing core in which the noise generator, amplifier and loudness suppression are signal processing features executed on the chip.
- FIG. 19 is an image depicting how sound travels through the device.
- FIG. 20 is a hypothetical graph depicting real ear measures capturing unaided gain (REUG), device occlusion (REOG), aided unity gain (REAG) and noise generator response (RENR).
- REUG unaided gain
- REOG device occlusion
- RMG aided unity gain
- RRR noise generator response
- FIG. 21A-D are a series of images depicting an adaptive hearing aid fitting (AHAF) strategy, designed to increase prescriptive gain progressively and incrementally as the hearing-aid user's dynamic range (DR) expands over the course of a proven sound therapy intervention, with the input/output and gain prescription using DSL 5.0 (4000 Hz).
- AHAF adaptive hearing aid fitting
- FIG. 21A-D are a series of images depicting an adaptive hearing aid fitting (AHAF) strategy, designed to increase prescriptive gain progressively and incrementally as the hearing-aid user's dynamic range (DR) expands over the course of a proven sound therapy intervention, with the input/output and gain prescription using DSL 5.0 (4000 Hz).
- AHAF adaptive hearing aid fitting
- the AHAF protocol can be modeled using the example of a sensorineural hearing-loss patient, RR, from Formby and Gold (2002).
- AHAF begins with current best practices (BP) fitting per the Desired Sensation Level (DSL) m[i/o] algorithm, which is the most widely accepted prescriptive strategy incorporating actual LDL judgments. Shown in the left column is the BP fit based on audiometric and LDL data for RR prior to sound therapy. Inputs to the DSL algorithm, taken from the panel A inset, are his measured pure-tone thresholds and LDL values at 4000 Hz. The resulting input/output (i/o) aided response is shown in panel A and the companion input/gain function is shown in panel B after DSL prescriptive fitting of target gain per BP.
- BP Desired Sensation Level
- LDL values measured at 4000 Hz for RR which are now used as the input values to the DSL prescription.
- LDL values measured at four time points during sound therapy, are depicted in the panel C inset as a set of color-coded idealized loudness growth functions; the respective functions highlight the incremental sound therapy-driven changes in the DR.
- the corresponding color-coded family of time-dependent, treatment-driven i/o functions is shown in the main panel C and the associated family of gain functions prescribed by DSL is shown in panel D.
- the prescriptive output increases systematically more for high-level sound inputs and less for low-level inputs, while aided gain changes from strongly nonlinear (negatively sloping) towards linear (flatter) as a consequence of the treatment-driven changes in the DR.
- FIG. 22 is a flow chart illustrating a generic implementation of targeted feature-specific sensory therapy.
- the term “comprising” is intended to mean that the products, compositions and methods include the referenced components or steps, but not excluding others. “Consisting essentially of” when used to define products, compositions and methods, shall mean excluding other components or steps of any essential significance. “Consisting of” shall mean excluding more than trace elements of other components or steps.
- Patient is used to describe a human to whom treatment is administered.
- patient and subject are used interchangeably herein.
- Sound generator or “noise generator” are used interchangeably herein to refer to a circuit that produces noise/sounds at various frequencies.
- the noise generator is used to provide a constant low-level white noise to the patient through use of the loudness suppression device described herein.
- Earmold refers to a device made of pliable material that can be inserted into the outer portion of a human ear and mold itself to the shape of the ear canal.
- Open mold refers to an earmold made of soft, pliable material that can be inserted into the outer portion of the ear and having open portions along the base of the earmold to allow some sound to pass through. The flow of sound through the natural or direct sound path is referred to as venting. An open mold has maximum venting.
- “Closed mold” as used herein refers to an earmold made of soft, pliable material that can be inserted into the outer portion of the ear.
- the earmold contains a body heat activated stint that expands in the ear for a snug fit and occludes the ear canal.
- a closed mold has minimal venting.
- SNHL sensorineural hearing loss
- Amplification is normally used to treat reduced audibility
- WDRC wide dynamic range compression
- DR reduced dynamic range
- ILDs interaural level differences
- FIG. 6 illustrates the hyper-gain system in which both emotional associations and physiological responses are a part of the hyper-gain system.
- the sound therapy is a passive process, first breaking the connection with the physiological reactions that are controlled by the autonomic nervous system followed by habituation of the patient's elevated emotional associations to sounds, which over time results from habituation of the negative connections with the limbic system.
- FIGS. 7 and 8 As these connections are habituated, the gain in the central auditory system is being recalibrated and gradually decreases. As a result, the gain returns toward its normal state, and sounds of all kinds are processed and perceived in a normal way in the high cortical areas.
- the treatment protocol is used to get the patient to a point where sounds are no longer uncomfortable. It is important to mention that the recalibration of the gain is not the direct result of habituation of physiological response (HR) and habituation of emotional associations (HE), but it facilitates the habituation process.
- HR physiological response
- HE habituation of emotional associations
- the low-level sound therapy and chronic exposure to healthy sound are the principle drivers of the gain recalibration.
- Sound therapy is achieved by exposing the auditory system to a non-annoying, low-level sound. These soft levels are activated by healthy sound exposures, initially under controlled conditions in the patient's home, and with an ear-worn device used in both ears.
- the device incorporates a sound generator that emits a soft sound similar to what is heard when putting a seashell to one's ear.
- the device also includes a limiter or compressor that restricts exposure to loud sounds, protecting the patient from offending sounds during treatment.
- FIG. 10 illustrates how loudness is perceived for individuals with normal sensitivity versus individuals with hyperacusis and how loudness is perceived when one wears earplugs versus using sound generators.
- FIG. 11 depicts an example of a person with hyperacusis and hearing loss. As noted in the image, the reports do not join the normal curve, but instead reach uncomfortable levels at a much lower level thus the reduced dynamic range is both due to the hearing loss and the lower LDL.
- the patient is given an audiometric test in which the patient is presented with different frequencies of sounds and asked to detect the lowest sound at each frequency which becomes the patient's threshold. When the patient hears a sound during the test, they raise a hand or push a button.
- An audiogram is formed from the results of the audiometric test which depicts frequencies of sound that are heard by the patient in a graph form. The audiogram depicts how loud sounds need to be at different frequencies in order for the patient to hear them.
- the audiogram illustrates the type, degree and configuration of hearing loss.
- a marker, such as a dashed line, at 20 dB shows the limit of normal hearing. If the patient's thresholds are below this dashed line then there is some degree of hearing loss.
- young normal hearing people have their thresholds at 0 dB.
- one color for example a red color
- another color for example a blue color
- two different audiograms can be used, one for the right ear and one for the left as in FIG. 12 .
- the frequencies, which correspond to the perceived pitches of the sounds are measured in Hertz.
- the low frequencies located toward the left represent sounds such as the vowels “aa, oo” while the high frequencies located toward the right represent sounds in speech such as the consonants “ss, sh”.
- the y-axis is used to measure the intensity of the sound in decibels, i.e. the amount the level of the sound had to be increased for the patient to hear it. Going downward on the vertical axis the intensity increases as shown by the increasing decibel values.
- Speech tests are also performed on the patient to demonstrate the ability to detect speech and understand it at conversational levels.
- the speech reception thresholds closely agree with hearing thresholds at the primary frequencies that are critical in understanding speech. Results of the speech tests are given in the context of the percentage the patient was able to understand and repeat the number of words presented at a conversational level. This information is important especially for hearing aid fitting.
- LDLs loudness discomfort levels
- FIG. 13 The range between the threshold, where the patient barely heard the sound and the “U” symbol, where the sound became uncomfortable, is the dynamic range.
- these LDLs are around 100 dB HL for most individuals.
- the LDLs are lower than about 90 dB, individuals may have problems tolerating louder sounds. Hyperacusis can manifest with reduced LDLs at all frequencies and in both ears.
- a patient may have thresholds that are normal, so they can hear soft sounds at a soft level, but as the intensity of sound increases, a level is reached quicker than usual and becomes uncomfortable, which accounts for the patient's limited dynamic range and explains intolerance to moderate and loud sounds.
- the LDLs increase with time and the patient's adverse reaction to sounds slowly subsides as the hyperacusis condition improves.
- the patient may have some hearing loss that requires a higher than normal level to hear soft sounds, and then as the intensity of a sound increases, a level is very quickly reached where sounds may become uncomfortable. Because of the hearing loss, the patient would have a limited dynamic range that contributes to intolerance to moderate and loud sounds. If the patient uses a hearing aid then it will amplify sounds (it will make them louder) at different frequencies, which may become loud and uncomfortable thus limiting how much amplification can be used.
- the inventors have developed a system and method for patients suffering from hyperacusis including hearing loss, reduced sound tolerance and restricted dynamic range resulting from primary hyperacusis, hyperacusis associated with misophonia or photophonia, and hyperacusis with or without hearing loss. Exposure to safe, healthy sounds over time decreases the auditory system's gain and improves the patient's tolerance to sounds.
- the method uses the plasticity of the auditory system to increase the patient's LDLs and to ensure that the patient is comfortable with all kinds of sounds, as was the case prior to the hyperacusis.
- the treatment is patient-dependent, meaning that amount of use of the devices may differ for each patient in order to receive the treatment benefit.
- the system uses a novel in-ear device having both loudness suppression and a sound generator for sound therapy in conjunction with a specific counseling protocol and fitting protocol that is patient-specific.
- the treatment involves counseling and exposing the patient to a healthy sound environment, including to low level, broadband sound from ear-worn devices that will initiate plastic changes within the patient's auditory system.
- the goal of the treatment is to increase the patient's LDLs to normal levels thus expanding the dynamic range (range between the patient's thresholds and uncomfortable levels) and allowing the patient to hear soft, moderate and loud sounds normally.
- the expanded DR can be shown by incremental shifts in LDL values.
- an existing earplug is replaced with an earmold that functions as a high quality plug that is connected to a device having loudness suppression as well as a sound generator and amplification (hearing aid).
- amplification is used to achieve unity gain with no attenuation implemented unless necessary.
- the patient's full dynamic range is respected, and output limiting is relied on to reduce exposure to loud sounds (loudness suppression).
- the sound generator is relied on to expand the dynamic range over time with the loudness suppression systematically released as the dynamic range expands.
- the patient is gradually weaned off of earplugs, muffs, and loudness suppression.
- An expanded dynamic range also increases the possibility of amplification with comorbid hearing loss.
- Real-ear verification is important due to the differences in ear canal resonances that are caused by differences in shape, size and elasticity of individual patients; differences in concha/pinnae resonance effects and inadequate control of coupling/venting with prescribed settings. It has been shown that without real-ear verification, 74% of reference fittings vary from the prescription by 10 dB or more at one or more frequencies. Real-ear verification leads to increased patient satisfaction, improved audibility, objective documentation of device performance and a lower rate of return.
- Earplugs are counterproductive for treatment as earplugs reduce the sound input to the brain and the brain compensates to the reduced input by increasing the gain.
- the goal of the therapy is to protect the patient's ears appropriately and to use ear protection only when the patient is exposed or expects to be exposed to loud sounds that may harm hearing.
- the devices limit the patient's exposure to offending sounds that are uncomfortable, thus earplugs should be unnecessary during treatment.
- the novel device described herein is capable of offering hyperacusis patients a fully integrated instrument capable of spanning continuum of management and treatment from sound attenuation to enrichment.
- the inventors have engineered a behind-the-ear (BTE) loudness suppression (LS) device 10 with slim tubing 40 , being about 0.9 mm, that supports two interchangeable earmolds.
- BTE behind-the-ear
- LS loudness suppression
- the signal processing core containing an amplifier 70 is combined with a ferrofluid receiver 90 and at least one MEMs microphone 80 housed, along with a battery 100 , in a BTE shell 50 .
- FIG. 17 At least one MEMs microphones 80 , receiver 90 and noise generator 60 are separate components that are electrically connected to the signal processing core chip containing an amplifier 70 via wires as shown in FIG. 18 .
- the primary “closed” mold 20 comprises an earmold that includes a patented body-heat-activated expanding stint provided by General Hearing Instruments (GHI). ( FIG. 15 ). This technology improves comfort while maintaining a tight seal in the canal to increase passive attenuation.
- a sound generator (SG) 60 is contained within BTE shell 50 to generate noise. With device 10 , subjects can receive the required attenuation with an ear plug function when device 10 is powered off or muted and active loudness suppression (LS) via output limiting compression and sound therapy via sound generator (SG) treatment.
- FIG. 19 depicts how sound flows through the device.
- the secondary open mold 30 minimizes sound attenuation, preserves SG acoustic characteristics, and allows healthy environmental sound exposure (without compression) as desired by the subjects in safe quiet environments that they can control when LS is not needed. ( FIG. 16 ).
- the ability to use two swappable earmolds promotes the use of the therapeutic sound generator 60 as frequently as possible while providing either attenuation of offending sounds or healthy exposure to comfortable sounds.
- Shells include a reusable and pluggable probe-microphone tube port to enable in-situ measurement and calibration of key electro-acoustic parameters.
- the unity gain is the frequency specific gain sufficient to overcome earmold attenuation.
- a unity gain-frequency model is used in the device that compensates for the primary occlusion attenuation (i.e., insertion loss) provided with the closed mold.
- the iterative algorithm measures the real-ear occluded response (REOR) and automatically adjusts gain to achieve the original real-ear unaided response (REUR).
- REUR natural gain
- REOR eyeplug effect
- the “kneepoint” compression threshold for activating LS is set based on individual, frequency-dependent loudness judgments and verified using test-box measures. In-situ verification of NG output produces the Real Ear Noise Response (RENR; black curve). Overall NG level is calibrated within +/ ⁇ 2 dB of the target frequency response.
- RRR Real Ear Noise Response
- the digital signal processing (DSP)-based solution uses n channels of amplitude compression in conjunction with more sophisticated attack and release algorithms, thus reducing potential activation/deactivation annoyance.
- DSP digital signal processing
- output compression any algorithmic modification to the signal path is subject to LS compression via output limiting, thereby guaranteeing no risk of over-attack phenomena, even when implementing an infinite-to-1 compression ratio (CR) thereby overall performance is improved when operating as a loudness suppression (LS) device.
- the LS compression threshold will be adjustable and more than capable of replicating the 65-dB limiting threshold reported by Sammeth et al.
- the LS compressor parameters of kneepoint as a function of frequency and ratio as a function of frequency are adaptive over time based on treatment-induced changes in loudness perception.
- the use of this LS processing in this invention is uniquely tied to the treatment-induced changes in loudness discomfort levels that are measured periodically and used to progressively release the LS by adjusting the frequency-dependent kneepoint according to the magnitude of the treatment effects derived from the unique combination of the counseling and SG use.
- Devices include a broadband SG algorithm, with filtering to fine tune the spectral shape and output levels to match the closed- and opened-mold conditions within subject, user-specific comfort levels corresponding to categorical loudness judgements of “soft but comfortable”, and a user-control toggle to allow participants to make small (e.g., ⁇ 3 dB) adjustments in noise level as needed and/or to briefly mute the device.
- the function of the SG is to induce changes in auditory processing that lead to increased sound tolerance and expanded dynamic range over long-term SG use. SG use is the primary therapeutic agent of this invention.
- a low-noise system is desired as system noise would otherwise be audible and potentially bothersome when and if the device is used without the SG active.
- Main sources of unwanted noise are microphone circuit noise and digital-to-analog (D/A) converter noise.
- IRN input-referred noise
- IRN input-referred noise
- a lower-power receiver is used to alleviate this risk.
- the low-gain nature of these devices should result in noise levels close to imperceptible. If it is determined that the noise level is too high, then a low-level expansion algorithm can be used to attenuate further the device self-noise in quiet environments.
- Data logging records usage (hours) separately for the closed- and opened-mold conditions to monitor protocol compliance and ambient sound levels for each condition.
- Device data logging is an important component in the process of determining treatment dosage.
- Inclusion of a toggle switch supports adjustment of SG level and inclusion of a “panic” button allows the user in the primary LS mode to disable UG, effectively reverting to maximum attenuation from a well-fitted EP.
- the treatment protocol consists of five main elements: evaluation, sound generator counseling, loudness suppression counseling, loudness suppression device fitting, and sound generator device fitting. The protocols for each will be described below.
- the evaluation protocol includes a full audiometric and hyperacusis evaluation. Audiometric evaluation is needed to provide indices of hearing sensitivity needed for device fitting and counseling. Tone decay assessment is performed to ensure that perception of the therapeutic SG will be maintained for prolonged periods of time. The presence of abnormal tone decay is a contra-indication of this treatment. Frequency-specific and ear-dependent loudness discomfort levels (LDLs) are measured and used as input parameters to the LS device algorithm. If LDL measurement is contraindicated, then loudness category six values can be used on the basis of the Contour Categorical Loudness test (Cox et al. 1997).
- LDLs Frequency-specific and ear-dependent loudness discomfort levels
- the evaluation protocol should also include one or more questionnaires that evaluate, at a minimum, loudness tolerance and quality-of-life to be used on the counseling portion of the treatment protocol.
- the primary purpose of the sound generator is to expand the patient's loudness tolerance. It is important that the SG counseling precedes LS counseling.
- the SG component of the devices provides a soothing, seashell-like background sound that provides minimal but constant stimulation to the auditory system including the parts of the brain that are involved in processing and interpreting sound. Prolonged use of SG devices increases loudness tolerance in patients with hyperacusis, even when they have normal hearing thresholds or hearing loss.
- the SG is set to a soft, comfortable level during the fitting process and works the same way with either of two different ear mold systems (open or closed). The more the patient uses the SG, the greater the improvement in loudness tolerance. Improvement in loudness tolerance is the primary goal of this treatment. Secondary goals include reduced use of attenuating devices and the ability to comfortably experience a wider range of sound levels in normal daily life.
- the devices After acclimating to treatment, the devices should be worn for a minimum of 8 hours each day or longer if comfortable. It is advised to wear the devices as long as possible during the waking day, preferably for a minimum of 8 hours which do not need to be consecutive hours.
- the open mold is used only when the patient is in a quiet environment where they can control their exposure to uncomfortably loud sounds.
- the closed mold is used when there is a risk of the patient being exposed to loud sounds.
- the protective loudness suppression feature works only with the closed mold whereas the sound generator is used with both the open and closed molds to provide treatment.
- the output of the devices are preset so there is no volume control for the patient to adjust. It is preferable for the patient to avoid unnecessarily removing and inserting the devices multiple times a day. The patient may or may not hear the sound generated by the treatment devices over time, either of which is a normal process.
- Sound therapy from the sound generators can be reinforced by the use of healthy environmental sound from other sources such as fans, sound machines, air conditioners, nature recordings, humidifiers, fountains, aquariums, sound pillows, etc. There always should be healthy sound exposures for the auditory system, which are critical for maintaining normal sound tolerance.
- the volume of the devices are preset to a soft level that is just above the point where the patient starts to hear it. Once the volume is set, the patient is unable to adjust it until the next clinic visit so it is important that an acceptable volume is set for each of the devices so that the patient experiences equal loudness for both ears.
- the patient may stop hearing the noise sound from the treatment devices after a short period of time as it is normal for the brain to “tune out” the sound as this is a sound that the brain tries to control.
- the patient When the patient is surrounded by normal environment sounds, they may not be aware of the sound emanating from the devices as the normal environment sounds may cover the sound of the devices. However, the devices should always produce sound.
- LS The purpose of LS is to limit exposure to uncomfortably loud sounds in sound environments that the user cannot control. Over the course of treatment with the sound generators, the goal is to reduce reliance on LS as the patient's sound tolerance improves. This process is slow and gradual as the patient adjusts to being exposed to healthy and comfortable but louder sounds. For safety, if the patient unexpectedly experiences an uncomfortably loud sound or sound environment, there is an “off toggle” on the device that can be used in the closed mold system to turn off the device, which effectively allows the device to perform as a well-fit, strongly-attenuating earplug. Neither the protective closed mold system nor LS are providing treatment. Rather, these systems reduce exposure to offending sounds by reducing their level. The low-level sound from the sound generators provides the treatment and therefore the sound generators should be used as much as possible each day with one or the other earmold systems.
- LS device 10 is worn behind the ears and it is custom fit to the patient's ears and hearing. Two different earmolds are used at different times.
- One earmold system, closed earmold 20 is fashioned like an ear plug and functions as an ear plug when the device is turned off.
- One purpose of closed ear mold 20 is to reduce the level of all sounds when device 10 is powered off, the same as a traditional earmold.
- Closed earmold 20 can be used with LS device 10 to form a closed earmold system which provides normal exposure to comfortable sound levels while at the same time limiting exposure to uncomfortably loud sounds.
- the second earmold system is an open earmold 30 that is used when the patient is listening to soft and comfortably healthy sound levels when in a controlled, low-level sound environment, such as the patient's home. Under these controlled conditions, the LS is not activated.
- the purpose of open earmold 30 is to allow the patient to continue to wear LS device 10 at times when the patient would not want or feel the need to wear an earplug.
- Open earmold 30 can be used with LS device 10 to form an open earmold system which is used when the patient does not anticipate exposure to uncontrolled sound environments.
- the closed-mold system is used whenever the patient expects they may be exposed to uncontrolled sound environments, including environments in which the patient currently uses ear plugs.
- One of the earmold systems (closed or open) should be used as much as possible throughout the day while the patient is awake to allow the patient to receive maximum treatment effects from the SG.
- the patient may not wish to use the LS devices 10 for prolonged periods of time if they feel uncomfortable with the earmolds in their ears.
- the patient can build up use of the devices 10 each day toward a goal of device usage at least 8 hours a day, and then to the recommended goal of device usage throughout the waking day. Full benefit of the treatment is dependent on prolonged use of the devices on a daily basis.
- Each LS device 10 is marked for either the left or the right ear.
- the LS device shell 50 is slipped behind the top of the ear with tubing 40 hanging down in front of the ear.
- the soft dome flex tip of earmold should point toward the opening of the ear canal into which it is gently inserted until polytube 40 is flush with the outer ear.
- the patient may need to pull the top of the ear with their hand to allow for easy insertion into the ear canal. It is important not to expose the devices to water or high temperatures or humidity. The devices can be inspected each night and the polytube removed and cleaned to remove debris.
- sound generator 60 is activated and baseline outcomes are measured by several means including audiometrics; questionnaires related to hyperacusis, tinnitus, QOL, distress and anxiety; contour categorical loudness as a basis for LS release and to establish presentation level for connected speech test (CST); CST at categories 4 and 6; and device usage. Loudness suppression is released about every 4 weeks with outcome measures being taken about every 8 weeks, dependent on how the patient progresses.
- LS fitting requires established communication between the ear-level devices, the fitting software, and the probe-microphone hearing instrument verification software/hardware system. Prior to LS fitting, the patient should have undergone LS device counseling. General instructions for this evaluation should include a description of the nature of this session, goals for device fitting and verification, and description of the sounds to be heard during the session.
- the device is connected to the programming computer with communication being established between (1) the fitting software on the computer and the device and (2) the fitting software and software controlling a probe microphone (real-ear) hearing aid verification system.
- the probe-microphone system is recalibrated according to manufacturer specification before each session.
- the fitting software is preloaded with patient fitting data from the previous fitting or re-fitting session and the patient is seated in front of the real-ear system. Otoscopy and any necessary cerumen management is completed prior to the session.
- the probe tube assembly is secured, and the probe tube is positioned such that probe tube is at least 5 mm from the end of the earmold terminus but does not contact the tympanic membrane.
- a first ear is chosen for fitting and verification.
- the first measurement is for the real-ear unaided response (REUR). Measurement is conducted by running a speech signal for leveling as a stimulus to account for the difference between the reference microphone at calibration versus in situ. The stimulus is run for only 1 second without recording and the measurement is stopped once the curve is visualized. The stimulus is then changed on the same curve and the measurement is conducted and recorded to obtain the REUR curve.
- REUR real-ear unaided response
- the real-ear unaided response is measured using a broadband noise from the verification system as described above.
- the earmold is inserted into the patient's ear and sufficient time is allowed for the heat-activated stint to engage and expand.
- the second measurement is sound generator (SG) calibration preceded by an estimation of the verification noise floor.
- Knowledge of the verification system noise floor is essential for interpretation of each of the subsequent measurements. All measurement stimuli must be above the system noise floor at all relevant frequencies and below the loudness tolerances of the patient.
- a speech stimulus is used to measure the verification noise floor. This measurement is then compared to an estimate of the noise floor in the software as well as KEMAR noise floor.
- the SG In order to calibrate the SG, the SG is unmuted, and a white noise stimulus is administered. The curve of the SG calibration noise is then measured and recorded.
- the next measurement is to record the real-ear occluded response (REOR), have the patient insert both ear molds, with the non-test ear functioning as an earplug, in order to avoid overstimulation via the test stimulus. Mute the SG and amplifier of each hearing device and measure the REOR using a broadband or white noise from the verification system speakers.
- REOR real-ear occluded response
- Unity gain combined with LS, allows normal exposure to soft and comfortably loud input sounds and loudness suppression of input sounds that exceed patient tolerance.
- RRR real-ear aided response
- the patient is instructed on the sounds to be heard.
- the SG is muted, and the microphones/amplification are unmuted.
- Real-ear aided response (REAR) is measured to broadband or white noise stimulus that is presented at a suitable level.
- loudness category levels 1-4 are assessed with the patient making a judgment as to how loud the sound is as it increases. Each increase is by 2 dB.
- the gain-frequency response is adjusted so that the REAR matches the REUR curve as needed to achieve unity gain. This gain effectively overcomes the earplug attenuation associated with the occluding ear mold and results in real-ear insertion gain (REIG) that is 0 dB across frequency.
- REIG real-ear insertion gain
- the output limit in the software is initially set to the required level (e.g. 65 dB) for high inputs (e.g. 90 dB) on the basis of LDL or loudness category 6 categorical judgments.
- a relatively high-level speech stimulus from the verification device is first administered followed by a slow release (decrease) output limiting from a low output limit until the patient reports that the loudness of the speech is a category 6 (“loud, but ok”).
- the response curve for high level speech is measured to verify that hearing output does not exceed the previously set output limit.
- the LS compression thresholds for each subject are set at levels based on their individual, frequency-specific, loudness discomfort levels, to limit higher level sound exposures similarly to exposures limited by his/her sound attenuators pretreatment.
- the LS compression thresholds are increased systematically (based on treatment-related improvements in each subject's loudness judgments measured periodically) to reduce the effect of compression, thereby gradually increasing exposure to higher-level healthy sounds.
- higher LS compression thresholds transition the patient to normal (compression-free) hearing, essentially weaning the patient off of the pretreatment sound attenuators and preparing the patient for any needed amplification as a result of comorbid hearing loss (if it exists).
- SG fitting requires established communication between the ear-level devices, the fitting software, and the probe-microphone hearing instrument verification software/hardware system.
- the patient Prior to SG fitting, the patient should have undergone SG device counseling.
- the SG should be set to a very low level and shaped according to the desired frequency response.
- the SG should be enabled and gradually increased by about 2 dB.
- the patient For each increase, the patient should provide categorical loudness judgments and the SG level should be set to a level corresponding to the category comfortable, but soft.
- the patient should be reminded that their perception of the sound may fade with time, so it's important for the sound to be audible and not too soft (Contour Test Category 3—“comfortable, soft”) when initially setting the SG level.
- the device is connected to the programming computer with communication being established between (1) the fitting software on the computer and the device and (2) the fitting software and software controlling a probe microphone (real-ear) hearing aid verification system.
- the probe-microphone system is recalibrated according to manufacturer specification before each session.
- the patient has completed LS device counseling.
- connectivity is established between the fitting software and the verification system.
- the fitting software is preloaded with patient fitting data from the previous fitting or re-fitting session and the patient is seated in front of the real-ear system. Otoscopy and any necessary cerumen management is completed prior to the session.
- the probe tube assembly is secured, and the probe tube is positioned such that probe tube is at least 5 mm from the end of the earmold terminus but does not contact the tympanic membrane.
- a first ear is chosen for fitting and verification. Knowledge of the verification system noise floor is essential for interpretation of each of the subsequent measurements. All measurement stimuli must be above the system noise floor at all relevant frequencies and below the loudness tolerances of the patient.
- both devices are muted, and the sound generator is off.
- the earmold is inserted into the patient's ear and sufficient time is allowed for the heat-activated stint to engage and expand.
- the device to be set is unmuted and placed in the first ear.
- the patient In order to set the SG level of the first device, the patient is first instructed to establish the level at which the SG is perceived to be comfortable but soft according to the Contour Loudness Test (Category 3). The SG level is then varied by about +/ ⁇ 2 dB to establish loudness categories 1 to 4. The patient is instructed that the perception of the sound will fade with time, so it is important for the sound to be audible and not too soft during this step.
- the SG/therapy noise is adjusted to have the desired spectral shape and the SG is activated at a low level. Categorical loudness judgments are obtained and the real-ear sound generator (RESG) level is measured to quantify SG output.
- RSG real-ear sound generator
- both devices are balanced by activating both devices simultaneously which comprises muting the SG and turning on both devices then turning on the SG in both devices and asking the patient if one device is louder than the other. If the SG in one device is louder than the other device, then the two devices are adjusted to have equal loudness.
- FIG. 12 illustrates an example of a patient who had tinnitus and hyperacusis. As noted in the image, the patient's LDLs were low at the beginning of the treatment and then improved over the course of treatment.
- the system and method can be applied to other patient groups including those patients having autism who have a hypersensitivity to sound as well as hunters who require situational awareness as the loudness suppression can protect the individual from loud sounds.
- a patient presents with primary hyperacusis and is evaluated by administration of audiometric evaluation as well as custom questionnaires.
- the audiometric evaluation includes determining both unoccluded and occluded (using the patient's current earplugs) thresholds, loudness determinations, and speech determinations. Tone decay is also determined. Ear canal impressions are made for ordering custom closed and open earmolds.
- counseling both LS and SG
- the LS device is fit to the patient using real-ear measures with the unity gain (UG) frequency response being achieved by adjusting the REAG to compensate for the REOG, thereby reproducing REUG (offsetting the insertion loss) for the closed mold LS condition as detailed in the LS fitting protocol.
- the LS device with UG will replace the patient's current sound attenuation (earplugs/muffs).
- the LS device offers enhanced audibility and a larger dynamic range.
- Initial LS threshold parameters are determined on the basis of loudness judgments for “loud but ok” (Contour Category 6) measured bilaterally from 250 to 8000 Hz, with SPL values verified via hearing instrument test measures (Audioscan VF-2). Counseling on device use, care, and expectations will be provided. LS devices may be worn for between 2 weeks to about one month before activation of the sound generators (SGs). Counseling for SG is provided to the patient prior to SG fitting according to protocol provided. Sound generators are activated with the SG set to a very low level and shaped according to the desired frequency response. The SG should be enabled and gradually increased by about 2 dB.
- the patient For each increase, the patient should provide categorical loudness judgments and the SG level should be set to a level corresponding to the category comfortable, but soft. The patient should be reminded that their perception of the sound may fade with time, so it's important for the sound to be audible and not too soft (Category 3—“comfortable, soft”) when initially setting the SG level.
- Category 3—“comfortable, soft” when initially setting the SG level.
- the patient is encouraged to wear the open earmold when in a safe sound controlled environment and the closed earmold when in an environment in which they may encounter unexpected high-level sounds with usage of both earmolds totaling at least 8 hours per day or as much as can be tolerated throughout the day.
- the patient is monitored at regular intervals for adjustments to be made to the loudness suppression as the dynamic range is expanded with the goal being that as the treatment effect is realized, higher LS compression thresholds transition the patient to normal (compression-free) hearing, essentially weaning the patient off of the pretreatment sound attenuators and preparing the patient for any needed amplification as a result of comorbid hearing loss (if it exists).
- the inventors have developed a patient-specific system and method of expanding the dynamic range in patients having a hypersensitivity to ordinary sound which utilizes a device having sound attenuation in conjunction with loudness suppression and a sound generator in conjunction with counseling. Expanding the dynamic range can be beneficial for any SNHL plus amplification.
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Acoustics & Sound (AREA)
- General Health & Medical Sciences (AREA)
- Otolaryngology (AREA)
- Signal Processing (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
REOR(f)=REUR(f)+α(f)
UG(f)=REOR(f)+γ(f)
where f=frequency, α=attenuation, and γ=gain.
TABLE 1 |
CONTOUR CATEGORICAL LOUDNESS SCALE |
Level/Category | |
1 | Very soft |
2 | Soft |
3 | Comfortable/soft |
4 | Comfortable |
5 | Comfortable/loud |
6 | Loud, OK |
7 | Uncomfortable |
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/450,023 US10582286B2 (en) | 2018-06-22 | 2019-06-24 | Method for treating debilitating hyperacusis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862688492P | 2018-06-22 | 2018-06-22 | |
US16/450,023 US10582286B2 (en) | 2018-06-22 | 2019-06-24 | Method for treating debilitating hyperacusis |
Publications (2)
Publication Number | Publication Date |
---|---|
US20190394551A1 US20190394551A1 (en) | 2019-12-26 |
US10582286B2 true US10582286B2 (en) | 2020-03-03 |
Family
ID=68982300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/450,023 Active US10582286B2 (en) | 2018-06-22 | 2019-06-24 | Method for treating debilitating hyperacusis |
Country Status (1)
Country | Link |
---|---|
US (1) | US10582286B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10582286B2 (en) * | 2018-06-22 | 2020-03-03 | University Of South Florida | Method for treating debilitating hyperacusis |
CN114745649B (en) * | 2022-03-22 | 2023-03-17 | 清华大学 | Real ear analysis test system based on coupling cavity microphone |
Citations (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5628330A (en) * | 1995-03-15 | 1997-05-13 | Upham; George W. | Apparatus for treating people afflicted with tinnitus |
US6048305A (en) * | 1997-08-07 | 2000-04-11 | Natan Bauman | Apparatus and method for an open ear auditory pathway stimulator to manage tinnitus and hyperacusis |
US6394947B1 (en) * | 1998-12-21 | 2002-05-28 | Cochlear Limited | Implantable hearing aid with tinnitus masker or noiser |
US6682472B1 (en) * | 1999-03-17 | 2004-01-27 | Tinnitech Ltd. | Tinnitus rehabilitation device and method |
US20040047482A1 (en) * | 2002-09-10 | 2004-03-11 | Natan Bauman | Hearing aid system |
US20040047483A1 (en) * | 2002-09-10 | 2004-03-11 | Natan Bauman | Hearing aid |
US20040141624A1 (en) * | 1999-03-17 | 2004-07-22 | Neuromonics Limited | Tinnitus rehabilitation device and method |
US20060167335A1 (en) * | 2005-01-26 | 2006-07-27 | Samsung Electronics Co., Ltd. | Method and device for tinnitus therapy |
US20070127755A1 (en) * | 2005-09-06 | 2007-06-07 | Natan Bauman | Tinnitus treatment device |
US20070133832A1 (en) * | 2005-11-14 | 2007-06-14 | Digiovanni Jeffrey J | Apparatus, systems and methods for relieving tinnitus, hyperacusis and/or hearing loss |
US20080205660A1 (en) * | 2006-06-22 | 2008-08-28 | Personics Holdings Inc. | Methods and devices for hearing damage notification and intervention |
US20110040205A1 (en) * | 2007-11-09 | 2011-02-17 | The City University | Treatment for Alleviating Tinnitus and Hyperacusis with Auditory Stimulation by Compensating for Hearing Loss and Loss of Non-Linear Compressions |
US20110071340A1 (en) * | 2009-09-22 | 2011-03-24 | Mcguire John F | Methods and systems for treating tinnitus |
US20110105967A1 (en) * | 2007-12-05 | 2011-05-05 | The Regents Of The University Of California | Devices and methods for suppression of tinittus |
US8218799B2 (en) * | 2007-08-22 | 2012-07-10 | Matthew Stephen Murphy | Non-occluding audio headset positioned in the ear canal |
US20120283593A1 (en) * | 2009-10-09 | 2012-11-08 | Auckland Uniservices Limited | Tinnitus treatment system and method |
US20120308060A1 (en) * | 2011-06-06 | 2012-12-06 | Oticon A/S | Diminishing tinnitus loudness by hearing instrument treatment |
US20130039517A1 (en) * | 2010-04-16 | 2013-02-14 | Widex A/S | Hearing aid and a method for alleviating tinnitus |
US20130072996A1 (en) * | 2008-07-02 | 2013-03-21 | The Board Of Regents, The University Of Texas System | Methods, Systems, and Devices for Treating Tinnitus with VNS Pairing |
US20130163797A1 (en) * | 2011-06-21 | 2013-06-27 | Tinnix, Inc. | Systems and Methods for Diagnosis and Treating Tinnitus |
US8503703B2 (en) * | 2000-01-20 | 2013-08-06 | Starkey Laboratories, Inc. | Hearing aid systems |
US20130336508A1 (en) * | 2012-06-14 | 2013-12-19 | Elizabeth Galster | User adjustments to a tinnitus therapy generator within a hearing assistance device |
US20140275737A1 (en) * | 2013-03-15 | 2014-09-18 | The Regents Of The University Of Michigan | Personalized auditory-somatosensory stimulation to treat tinnitus |
US20140363007A1 (en) * | 2005-11-14 | 2014-12-11 | Sanuthera, Inc. | Wearable device for relieving tinnitus, hyperacusis and/or hearing loss |
US20150005661A1 (en) * | 2013-02-22 | 2015-01-01 | Max Sound Corporation | Method and process for reducing tinnitus |
US20150003635A1 (en) * | 2013-06-28 | 2015-01-01 | Otoharmonics Corporation | Systems and methods for tracking and presenting tinnitus therapy data |
US20150120310A1 (en) * | 2011-07-08 | 2015-04-30 | Roger Roberts | Audio input device |
US20160030245A1 (en) * | 2013-03-15 | 2016-02-04 | Soundcure, Inc. | Devices and methods for suppressing tinnitus |
US20160249145A1 (en) * | 2015-02-23 | 2016-08-25 | Oticon A/S | Hearing instrument |
US20160255449A1 (en) * | 2013-03-15 | 2016-09-01 | Natan Bauman | Variable Sound Attenuator With Hearing Aid |
US20160366527A1 (en) * | 2015-06-09 | 2016-12-15 | Oticon A/S | Hearing device comprising a signal generator for masking tinnitus |
US20170071534A1 (en) * | 2015-09-16 | 2017-03-16 | Yong D Zhao | Practitioner device for facilitating testing and treatment of auditory disorders |
US20170171677A1 (en) * | 2015-12-11 | 2017-06-15 | Turtle Beach Corporation | Tinnitus treatment systems and methods |
US20170347213A1 (en) * | 2016-05-27 | 2017-11-30 | Michael Goorevich | Tinnitus masking in hearing prostheses |
US20170353807A1 (en) * | 2016-06-07 | 2017-12-07 | Regents Of The University Of Minnesota | Systems and methods for treating tinnitus and enhancing hearing |
US20180035216A1 (en) * | 2010-08-05 | 2018-02-01 | Ace Communications Limited | Method and system for self-managed sound enhancement |
US9913053B2 (en) * | 2007-03-07 | 2018-03-06 | Gn Hearing A/S | Sound enrichment for the relief of tinnitus |
US20180262854A1 (en) * | 2017-03-09 | 2018-09-13 | Sivantos Pte. Ltd. | Method for operating a hearing aid device, and hearing aid device |
US20180271710A1 (en) * | 2017-03-22 | 2018-09-27 | Bragi GmbH | Wireless earpiece for tinnitus therapy |
US20180288540A1 (en) * | 2017-03-31 | 2018-10-04 | Starkey Laboratories, Inc. | Automated assessment and adjustment of tinnitus-masker impact on speech intelligibility during fitting |
US10165372B2 (en) * | 2012-06-26 | 2018-12-25 | Gn Hearing A/S | Sound system for tinnitus relief |
US20190163952A1 (en) * | 2017-11-30 | 2019-05-30 | Sivantos Pte. Ltd. | Method for operating an apparatus for tinnitus characterization and corresponding apparatus |
US20190201657A1 (en) * | 2016-08-12 | 2019-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for hearing threshold-adapted acoustic stimulation |
US20190344073A1 (en) * | 2018-05-09 | 2019-11-14 | Otoharmonics Corporation | Method and system for tinnitus sound therapy |
US20190394551A1 (en) * | 2018-06-22 | 2019-12-26 | University Of South Florida | Method for treating debilitating hyperacusis |
-
2019
- 2019-06-24 US US16/450,023 patent/US10582286B2/en active Active
Patent Citations (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5628330A (en) * | 1995-03-15 | 1997-05-13 | Upham; George W. | Apparatus for treating people afflicted with tinnitus |
US6048305A (en) * | 1997-08-07 | 2000-04-11 | Natan Bauman | Apparatus and method for an open ear auditory pathway stimulator to manage tinnitus and hyperacusis |
US6394947B1 (en) * | 1998-12-21 | 2002-05-28 | Cochlear Limited | Implantable hearing aid with tinnitus masker or noiser |
US7520851B2 (en) * | 1999-03-17 | 2009-04-21 | Neurominics Pty Limited | Tinnitus rehabilitation device and method |
US6682472B1 (en) * | 1999-03-17 | 2004-01-27 | Tinnitech Ltd. | Tinnitus rehabilitation device and method |
US20040141624A1 (en) * | 1999-03-17 | 2004-07-22 | Neuromonics Limited | Tinnitus rehabilitation device and method |
US8503703B2 (en) * | 2000-01-20 | 2013-08-06 | Starkey Laboratories, Inc. | Hearing aid systems |
US20040047482A1 (en) * | 2002-09-10 | 2004-03-11 | Natan Bauman | Hearing aid system |
US20040047483A1 (en) * | 2002-09-10 | 2004-03-11 | Natan Bauman | Hearing aid |
US20060167335A1 (en) * | 2005-01-26 | 2006-07-27 | Samsung Electronics Co., Ltd. | Method and device for tinnitus therapy |
US20070127755A1 (en) * | 2005-09-06 | 2007-06-07 | Natan Bauman | Tinnitus treatment device |
US20140363007A1 (en) * | 2005-11-14 | 2014-12-11 | Sanuthera, Inc. | Wearable device for relieving tinnitus, hyperacusis and/or hearing loss |
US20070133832A1 (en) * | 2005-11-14 | 2007-06-14 | Digiovanni Jeffrey J | Apparatus, systems and methods for relieving tinnitus, hyperacusis and/or hearing loss |
US20080205660A1 (en) * | 2006-06-22 | 2008-08-28 | Personics Holdings Inc. | Methods and devices for hearing damage notification and intervention |
US9913053B2 (en) * | 2007-03-07 | 2018-03-06 | Gn Hearing A/S | Sound enrichment for the relief of tinnitus |
US8218799B2 (en) * | 2007-08-22 | 2012-07-10 | Matthew Stephen Murphy | Non-occluding audio headset positioned in the ear canal |
US20110040205A1 (en) * | 2007-11-09 | 2011-02-17 | The City University | Treatment for Alleviating Tinnitus and Hyperacusis with Auditory Stimulation by Compensating for Hearing Loss and Loss of Non-Linear Compressions |
US20110105967A1 (en) * | 2007-12-05 | 2011-05-05 | The Regents Of The University Of California | Devices and methods for suppression of tinittus |
US20130072996A1 (en) * | 2008-07-02 | 2013-03-21 | The Board Of Regents, The University Of Texas System | Methods, Systems, and Devices for Treating Tinnitus with VNS Pairing |
US20110071340A1 (en) * | 2009-09-22 | 2011-03-24 | Mcguire John F | Methods and systems for treating tinnitus |
US20120283593A1 (en) * | 2009-10-09 | 2012-11-08 | Auckland Uniservices Limited | Tinnitus treatment system and method |
US20130039517A1 (en) * | 2010-04-16 | 2013-02-14 | Widex A/S | Hearing aid and a method for alleviating tinnitus |
US20180035216A1 (en) * | 2010-08-05 | 2018-02-01 | Ace Communications Limited | Method and system for self-managed sound enhancement |
US20120308060A1 (en) * | 2011-06-06 | 2012-12-06 | Oticon A/S | Diminishing tinnitus loudness by hearing instrument treatment |
US20130163797A1 (en) * | 2011-06-21 | 2013-06-27 | Tinnix, Inc. | Systems and Methods for Diagnosis and Treating Tinnitus |
US20150120310A1 (en) * | 2011-07-08 | 2015-04-30 | Roger Roberts | Audio input device |
US20130336508A1 (en) * | 2012-06-14 | 2013-12-19 | Elizabeth Galster | User adjustments to a tinnitus therapy generator within a hearing assistance device |
US10165372B2 (en) * | 2012-06-26 | 2018-12-25 | Gn Hearing A/S | Sound system for tinnitus relief |
US20150005661A1 (en) * | 2013-02-22 | 2015-01-01 | Max Sound Corporation | Method and process for reducing tinnitus |
US20160030245A1 (en) * | 2013-03-15 | 2016-02-04 | Soundcure, Inc. | Devices and methods for suppressing tinnitus |
US20160255449A1 (en) * | 2013-03-15 | 2016-09-01 | Natan Bauman | Variable Sound Attenuator With Hearing Aid |
US20140275737A1 (en) * | 2013-03-15 | 2014-09-18 | The Regents Of The University Of Michigan | Personalized auditory-somatosensory stimulation to treat tinnitus |
US20150003635A1 (en) * | 2013-06-28 | 2015-01-01 | Otoharmonics Corporation | Systems and methods for tracking and presenting tinnitus therapy data |
US20160249145A1 (en) * | 2015-02-23 | 2016-08-25 | Oticon A/S | Hearing instrument |
US20190261105A1 (en) * | 2015-02-23 | 2019-08-22 | Oticon A/S | Method and apparatus for controlling a hearing instrument to relieve tinitus, hyperacusis, and hearing loss |
US20160366527A1 (en) * | 2015-06-09 | 2016-12-15 | Oticon A/S | Hearing device comprising a signal generator for masking tinnitus |
US20170071534A1 (en) * | 2015-09-16 | 2017-03-16 | Yong D Zhao | Practitioner device for facilitating testing and treatment of auditory disorders |
US20170171677A1 (en) * | 2015-12-11 | 2017-06-15 | Turtle Beach Corporation | Tinnitus treatment systems and methods |
US20170347213A1 (en) * | 2016-05-27 | 2017-11-30 | Michael Goorevich | Tinnitus masking in hearing prostheses |
US20170353807A1 (en) * | 2016-06-07 | 2017-12-07 | Regents Of The University Of Minnesota | Systems and methods for treating tinnitus and enhancing hearing |
US20190201657A1 (en) * | 2016-08-12 | 2019-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for hearing threshold-adapted acoustic stimulation |
US20180262854A1 (en) * | 2017-03-09 | 2018-09-13 | Sivantos Pte. Ltd. | Method for operating a hearing aid device, and hearing aid device |
US20180271710A1 (en) * | 2017-03-22 | 2018-09-27 | Bragi GmbH | Wireless earpiece for tinnitus therapy |
US20180288540A1 (en) * | 2017-03-31 | 2018-10-04 | Starkey Laboratories, Inc. | Automated assessment and adjustment of tinnitus-masker impact on speech intelligibility during fitting |
US20190163952A1 (en) * | 2017-11-30 | 2019-05-30 | Sivantos Pte. Ltd. | Method for operating an apparatus for tinnitus characterization and corresponding apparatus |
US20190344073A1 (en) * | 2018-05-09 | 2019-11-14 | Otoharmonics Corporation | Method and system for tinnitus sound therapy |
US20190394551A1 (en) * | 2018-06-22 | 2019-12-26 | University Of South Florida | Method for treating debilitating hyperacusis |
Non-Patent Citations (47)
Title |
---|
Alexander, Joshua M. and Katie Masterson. Ear Hear, 2015; 36(2): e35-e49. doi: 10.1097/AUD.0000000000000115. |
Andersson, G., et al., (2002). Hypersensitivity to sound (hyperacusis):A prevalence study conducted via the Internet and post. International Journal of Audiology. 41, 545-554. |
Bartnik, Grazyna et al. Distortion Product Otoacoustic Emission Levels and Input/Output-Growth Functions in Normal-Hearing Individuals with Tinnitus and/or Hyperacusis. Seminars in Hearing. Hyperacusis and Related Sound Tolerance Complaints: Differential Diagnosis, Treatment Effects, and Models, Nov. 2007; vol. 28, No. 4, pp. 303-318. |
Cox, R. M., et al., (1997). The contour test of loudness perception. Ear and Hearing. 18, 388-400. |
Dauman, R., and Bouscau-Faure, F. (2005). Assessment and amelioration of hyperacusis in tinnitus patients. Acta Oto-Laryngologica. 125, 503-509. |
Formby C., et al., A sound therapy-based intervention to expand the auditory dynamic range for loudness among persons with sensorineural hearing losses: a randomized placebo-controlled clinical trial, Seminars in Hearing, 2015, 26(2):77-109. |
Formby et al. Intervention for restricted dynamic range and reduced sound tolerance: clinical trial using a tinnitus retraining therapy protocol for hyperacusis. J. Acoust. Soc. Am., vol. 133, No. 5, Pt. 2, May 2013, 3382. |
Formby, C. and Gold, S., Modification of loudness discomfort level: Evidence for adaptive chronic auditory gain and its clinical relevance, Seminars in Hearing, 2002, 23(1):21-34. |
Formby, C. And Gold, S., Structured counseling for auditory dynamic range expansion, Seminars in Hearing, 2017, 38 (1):115-129. |
Formby, C. et al., Adaptive plasticity of loudness induced by chronic attenuation and enhancement of the acoustic background, J. Acoust. Soc. Am., Jul. 2003, 114(1):55-58. |
Formby, C. et al., Repeated Measurement of Absolute and Relative Judgments of Loudness: Clinical Relevance for Prescriptive Fitting of Aided Target Gains for soft, Comfortable, and Loud, But Ok Sound Levels, Seminar in Hearing, Feb. 2017;38(1):26-52. |
Formby, C., and Keaser, M.L., (2007). Secondary Treatment Benefits Achieved by Hearing-Impaired Tinnitus Patients Using aided Environmental Sound Therapy for Tinnitus Retraining Therapy: Comparisons with Matched Groups of Tinnitus Patients Using Noise Generators for Sound Therapy. Seminars in Hearing. 28(4), 276-294. |
Formby, C., and Scherer, R. TRTT Study Group; Rationale for the tinnitus retraining therapy trial. Noise Health. Mar.-Apr. 2013; 15(63): 134-42. |
Formby, C., et al., (2007). Adaptive recalibration of chronic auditory gain. Seminars in Hearing. 28(4), 295-302. |
Formby, C., et al., (2008). Intervention for restricted dynamic range and reduced sound tolerance. Proceedings of Meetings on Acoustics, The Acoustical Society of America, Acoustics '08 Paris, www.acoustics08-paris.org, pp. 4705-4709. |
Formby, C., et al., (2013). Intervention for restricted dynamic range and reduced sound tolerance: Clinical trial using a Tinnitus Retraining Therapy protocol for hyperacusis. Proceedings of the 21st International Congress on Acoustics, Proceedings of Meetings on Acoustics. 19(050083):1-5. |
Formby, C., Gold, S.L., Keaser, M.L., Block, K.L., and Hawley, M.L. (2007). Secondary benefits from Tinnitus Retraining Therapy (TRT): Clinically significant increases in loudness discomfort level and in the auditory dynamic range. Seminars in Hearing. 28(4), 276-294. |
Formby, Craig and Keaser, Michael L. Secondary Treatment Benefits Achieved by Hearing-Impaired Tinnitus Patients Using Aided Environmental Sound Therapy for Tinnitus Retraining Therapy: Comparisons with Matched Groups of Tinnitus Patients Using Noise Generators for Sound Therapy. Seminars in Hearing, Nov. 2007. vol. 28, No. 4, pp. 276-294. |
Formby, Craig et al. A Sound Therapy-Based Intervention to Expand the Auditory Dynamic Range for Loudness among Persons with Sensorineural Hearing Losses: A Randomized Placebo-Controlled Clinical Trial. Semin Hear. May 2015; 36(2): 77-110. |
Formby, Craig, et al. (2007). Adaptive Recalibration of Chronic Auditory Gain. Seminars in Hearing. 28(4), 295-302. |
Formby, Craig, et al. (2007). Secondary Benefits from Tinnitus Retraining Therapy: Clinically Significant Increases in Loudness Discomfort Level and Expansion of Auditory Dynamic Range. Seminars in Hearing. 28(4), 227-260. |
Gold, S., et al., (1999). Shifts in dynamic range for hyperacusis patients receiving tinnitus retraining therapy (TRT). In Hazell, J.W.P. (Ed.), Proceedings of the 6th International Tinnitus Seminar. London: The Tinnitus and Hyperacusis Centre, 297-301. |
Gold, S.L., et al. Incremental shifts in loudness discomfort level among tinnitus patients with and without hyperacusis. In Patuzzi, R. (Ed.), Proceedings of the 7th International Tinnitus Seminar. Crawley, W.A., Australia, Univ. Western Australia, (2002) pp. 170-173. |
Gold, S.L., et al., (2002). Shifts in dynamic range for hyperacusis patients receiving tinnitus retraining therapy (TRT). In Patuzzi R. (Ed), Proceedings of the 6th International Tinnitus Seminar. Cambridge, UK, British Society of Audiology,, pp. 297-301. |
Goldstein, B. And Schulman, A., Tinnitis-hyperacusis and the loudness discomfort level test-a preliminary report, International Tinnitis Journal, 1996, 2:83-89. |
Goldstein, B. And Schulman, A., Tinnitis—hyperacusis and the loudness discomfort level test—a preliminary report, International Tinnitis Journal, 1996, 2:83-89. |
Hamilton, A. M., and Munro, K. J., (2010). Uncomfortable loudness levels in experienced unilateral and bilateral hearing aid users: Evidence of adaptive plasticity following asymmetrical sensory input. International Journal of Audiology. 49, 667-671. |
Hawley, Monica L. and Keaser, Michael L. Predicting Hyperacusis in Tinnitus Patients. Seminars in Hearing. Hyperacusis and Related Sound Tolerance Complaints: Differential Diagnosis, Treatment Effects, and Models, Nov. 2007; vol. 28, No. 4, pp. 261-275. |
Hazell, J. W. P., et al., (2002). Decreased sound tolerance: predisposing factors, triggers, and outcomes after TRT. In Patuzzi R. (Ed), Proceedings of the Seventh International Tinnitus Seminar. Crawley, W. A., Australia: University of Western Australia, pp. 255-261. |
Hazell, J.W.P. and Sheldrake, J.B., Proceedings of the Fourth International Tinnitus Seminar, Bordeaux, France, Aug. 27-30, 1991, Kugler Publications, Amsterdam/New York, 1992; pp. 245-248. |
Hazell, Jonathan. Proceedings of the Sixth International Tinnitus Seminar hosted by the British Society of Audiology in Cambridge UK, Sep. 5-9, 1999. |
Jastreboff, P. J., and Jastreboff, M. M., (2000). Tinnitus retraining therapy (TRT) as a method for treatment of tinnitus and hyperacusis patients. Journal of American Academy of Audiology. 11, 162-177. |
Jastreboff, P.J., and Jastreboff, M.M., (2014). Treatments for decreased sound tolerance (hyperacusis and misophonia). Seminars in Hearing. 35, 10-120. |
Jastreboff, Pawel J. And Jonathan W.P. Hazell. A neurophysiological approach to tinnitus: clinical implications. British Journal of Audiology, 1993, 27, 7-17. |
Jastrehoff, PJ et al. Audiometrical characterization of hypercusis patients before and during TRT. Proceedings of the 6th International Tinnitus Seminar, Cambridge, UK, British Society of Audiology, pp. 495-498. |
Juris, L, et al., (2013). The Hyperacusis Questionnaire, loudness discomfort levels, and the Hospital Anxiety and Depression Scale: A cross-sectional study, Hearing, Balance and Communication, 11:2, 72-79, DOI: 10.3109/21695717.2013.780409 to link. |
McKinney, C. J., et al., (1999). Changes in loudness discomfort level and sensitivity to environmental sound with habituation based therapy. In Hazell, J.W.P. (Ed.), Proceedings of the Sixth International Tinnitus Seminar. London, UK: The Tinnitus and Hyperacusis Centre, pp. 499-501. |
Pienkowski, M., et al., (2014). A review of hyperacusis and future directions: Part II, measurement, mechanisms, and treatment. American Journal of Audiology. 23, 420-436. |
Sammeth, C. et al., Hyperacusis: Case studies and evaluation of electronic loudness suppression devices as a treatment approach, Scand. Audiology, 2000, 29:28-36. |
Sandlin, Robert E. and Robert J. Olsson. Evaluation and Selection of Maskers and Other Devices Used in the Treatment of Tinnitus and Hyperacusis. Trends in Amplification, vol. 4, No. 1, 1999, 6-26. |
Scherer, R.W., et al. Tinnitus Retraining Therapy Trial Research Group. The Tinnitus Retraining Therapy Trial (TRTT): study protocol for a randomized controlled trial. Trials. Oct. 15, 2014;15:396. |
Schmitz, H.D., (1969). Loudness discomfort level modification. J. Speech Hear. Res., vol. 12: 807-817. |
Sherlock, L and Formby, C., Estimates of loudness, loudness discomfort, and the auditory dynamic range: normative estimates, comparison of procedures, and test-retest reliability, J. Am. Acad. Audiol., 2005, 16(2):85-100. |
Silverman, S.R., (1947). Tolerance for Pure Tones and Speech in Normal and Defective Hearing. Annals of Otology, Rhinology and Laryngology; vol. 56, 658-677. |
Souza, Pamela E et al. Measuring the acoustic effects of compression amplification on speech in noise (L). J. Acoust. Soc. Am. 119(1), Jan. 2006, 41-44. |
Tyler, R. S., et al., (2014). A review of hyperacusis and future directions: Part I. definitions and manifestations. American Journal of Audiology. 23, 401-419. |
Wolk, C., and Seefeld, B., (1999). The effects of managing hyperacusis with maskers (noise generators). In Hazell, J.W.P. (Ed.) Proceedings of the Sixth International Tinnitus Seminar, London; England: The Tinnitus and Hyperacusis Centre, pp. 512-514. |
Also Published As
Publication number | Publication date |
---|---|
US20190394551A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kumpik et al. | A review of the effects of unilateral hearing loss on spatial hearing | |
Formby et al. | Adaptive plasticity of loudness induced by chronic attenuation and enhancement of the acoustic background (L) | |
DK2224987T3 (en) | Devices and methods for suppressing tinnitus | |
US20240205613A1 (en) | Distraction remediation at a hearing device | |
Arbogast et al. | Achieved gain and subjective outcomes for a wide-bandwidth contact hearing aid fitted using CAM2 | |
US10582286B2 (en) | Method for treating debilitating hyperacusis | |
Valente et al. | Evaluation and treatment of severe hyperacusis | |
Holgers et al. | Sound stimulation via bone conduction for tinnitus relief: a pilot study: Estimulación Sonora por vía ósea para mejorar el acúfeno: un estudio piloto | |
US20070019818A1 (en) | Device and method for configuring a hearing aid | |
Almuhawas et al. | Auditory performance and subjective satisfaction with the ADHEAR system | |
Rakszawski et al. | The effects of preprocessing strategies for pediatric cochlear implant recipients | |
CN106331972A (en) | Methods and devices for correct and safe placement of an in-ear communication device in the ear canal of a user | |
Valente et al. | Problems and solutions for fitting amplification to patients with Meniere's disease | |
Eddins et al. | Method for treating debilitating hyperacusis | |
Brookhouser et al. | Management of the child with sensorineural hearing loss: Medical, surgical, hearing aids, cochlear implants | |
Smeds et al. | Loudness and hearing loss | |
Popelka | SoundBite hearing system by Sonitus Medical: a new approach to single-sided deafness | |
RU2818251C1 (en) | Method of adjusting processors in bilateral cochlear implantation | |
Sataloff et al. | Hearing loss: Handicap and rehabilitation | |
Veugen | Bimodal Stimulation Towards Binaural Integration | |
Vidhya | Hearing Impairment | |
Schönwiesner et al. | Digital earplug for brain plasticity research | |
Gonçalves et al. | Tool Development for Human Audible Spectrum Compensation | |
Filomena Soares et al. | Tool Development for Human Audible Spectrum Compensation | |
Soares et al. | Tool Development for Human Audible Spectrum Compensation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORMBY, CHARLES CRAIG;REEL/FRAME:050177/0469 Effective date: 20190826 Owner name: UNIVERSITY OF SOUTH FLORIDA, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EDDINS, DAVID ALAN;REEL/FRAME:050177/0415 Effective date: 20190826 Owner name: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA, ALABAMA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FORMBY, CHARLES CRAIG;REEL/FRAME:050177/0469 Effective date: 20190826 |
|
AS | Assignment |
Owner name: SOUNDSGOOD LABS, INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ARMSTRONG, STEPHEN W.;REEL/FRAME:050800/0904 Effective date: 20191023 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF SOUTH FLORIDA;REEL/FRAME:068380/0570 Effective date: 20221128 |